Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
23 authors.
Xavier Y X SngInfection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0001-7424-2123
Valentina VoigtInfection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-2265-7914
Iona S SchusterInfection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0001-6219-9009
Peter FlemingInfection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-3230-9091
Felix A DeussInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-0386-4336
Mohammed H AbuwarwarInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-0852-8542
Serani L H van DommelenCentre for Experimental Immunology, Lions Eye Institute, Nedlands, Western Australia, Australia.ORCID 0000-0001-5165-9241
Georgia E G NeateInfection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0001-5439-9027
Riley M ArnoldInfection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0009-0003-2100-1467
Harry L HorsnellDepartment of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0002-4321-6958
Sheridan DalyCentre for Experimental Immunology, Lions Eye Institute, Nedlands, Western Australia, Australia.ORCID 0000-0002-9865-2124
Bagher GolzarroshanInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Antiopi VareliasQIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Stewart D LymanLyman BioPharma Consulting, Seattle, WA, USA.
Anthony A ScalzoCentre for Experimental Immunology, Lions Eye Institute, Nedlands, Western Australia, Australia.
Geoffrey R HillTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Scott N MuellerDepartment of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0002-3838-3989
Matthew E WikstromCentre for Experimental Immunology, Lions Eye Institute, Nedlands, Western Australia, Australia.ORCID 0009-0005-4545-8319
Richard BerryInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Jamie RossjohnInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-2020-7522
Anne L FletcherInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Christopher E Andoniou *Infection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia. chris.andoniou@monash.edu.ORCID 0000-0003-0566-3180
Mariapia A Degli-Esposti *Infection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia. mariapia.degli-esposti@monash.edu.ORCID 0000-0002-7808-5935
Funding
Defining Protective CMV Immunity after TransplantationR01AI175535 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Geoffrey Roger HILL · 2023 to 2026
$3.0M
National Health and Medical Research CouncilNHMRC investigator awardsNIAID NIH HHS R01 AI175535
6 · The paper itself
Abstract
The movement of dendritic cells and T cells within secondary lymphoid organs is critical for the development of adaptive immune responses
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Fibroblastic reticular cells direct the initiation of T cell responses via CD44. · full record | OpenQuestion